替尼泊苷（VM - 26）用于晚期难治性卵巢癌患者：荷兰卵巢癌联合研究组的一项II期研究
Teniposide (VM-26) in patients with advanced refractory ovarian cancer: a phase II study of the Netherlands Joint Study Group for Ovarian Cancer.
作者信息
van der Burg M E, ten Bokkel Huinink W W, Vriesendorp R, van Oosterom A T, Neijt J P, Vermorken J B, van Putten W L, Kooiman A
机构信息
Department of Medical Oncology, Rotterdam Cancer Institute, The Netherlands.
出版信息
Eur J Cancer Clin Oncol. 1987 Jul;23(7):997-8. doi: 10.1016/0277-5379(87)90348-8.
In 23 evaluable patients with advanced ovarian epithelial cancer refractory to combination therapy with cisplatin and an alkylating agent, teniposide (VM-26) was administered as a short-term i.v. infusion at a dose of 100 mg/m2 on days 1 and 2, every 3 weeks. Toxicity was moderate and comparable to the pattern known from other studies. No objective response has been observed, showing that teniposide is not active as second-line therapy in this disease.
在23例对顺铂和烷化剂联合治疗难治的晚期卵巢上皮癌可评估患者中，替尼泊苷（VM - 26）每3周在第1天和第2天以100 mg/m²的剂量进行短期静脉输注给药。毒性为中度，与其他研究已知的模式相当。未观察到客观缓解，表明替尼泊苷作为该疾病的二线治疗无效。
Zotero 插件